Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  DIRECTORS REPORT
Directors Report      
Global Health Ltd.
March 2020

Description of state of companies affair

For the FY 2019-20, the Company recorded revenue from operations of Rs.1,45,657.18/Lakhs (previous year Rs. 1,44,113.22/- Lakhs)resulting in an increase by 1.07%and net profit of Rs.10,275.67Lakhs(previous year Rs. 6,293.79 Lakhs)resulting in an increase by 63.27%on standalone basis.   The consolidated financials of the company includes the financials of Medanta Duke Research Institute Private Limited (MDRI), Global Health Patliputra Private Limited (GHPPL) and Medanta Holdings Private Limited (MHPL), being the subsidiaries of the Company.   The COVID-19 pandemic   outbreak during March 20 has affected countries across the Globe resulting in material impact on the healthcare industry in India as well due to travel restrictions imposed by the State / National /International Govt.(s) and deferment of elective surgeries / preventive health check-ups by people at large. Your Company has arisen to the situation and has taken a strong leadership in responding to the COVID-19 Management. All safety protocols / preventive / safety measures defined by regulatory bodies and the Company have been followed in providing best possible care for COVID / Non -Covid patients, clinical & non-clinical staff.   Separate wards have been established for COVID patients, E-clinic facility has been provided for home consultations, home care facility / post Covid rehabilitation facility has also been provided to COVID 19 patients by partnering with various Hotels. “Medanta - the Medicity” has been declared as the Best Private Hospital in India for the year 2020 by “Newsweek” and 2nd in all hospitals including Govt. Hospitals in India. Further, Medanta – the Medicity has been chosen as best Covid Care Hospital in India for “Safaigiri Award” by India Today. The financial impact of COVID 19 pandemic will be reflected during the FY 20-21.    

Details regarding energy conservation

CONSERVATION OF ENERGY   Steps taken or Impact on Conservation of Energy   The operations of the Company are not energy-intensive. However, significant measures have been taken to reduce the energy consumption by using energy-efficient equipments. The Company has implemented the following additional Energy Conservation Measures during the Financial Year 2019-2020.   Boiler and Kitchen fuel conversion from HSD/LPG to PNG (Piped Natural Gas)   One of the boiler burner was converted into PNG as fuel instead of HSD, which is proved to be safe and environmental friendly besides cost effective operations. There was savingof Rs: 1, 48, 80, 257.00 ( Rupees One Crore Forty Eight Lac Eighty Thousand Two Hundred Fifty Seven only) during the period (June-19 to May20).   The project cost :Rs 16, 72,904.00.   Proposal   DG Set fuel conversation kit installation for HSD and PNG both in 30:70 ratio for FY-2020-21   It is proposed for converting the DG sets with duel fuel kit. HSD and PNG shall be used to run DG Set in ratio of 30:70.It will result in saving of Rs. 17 lacs - 27 Lacs per year approximately depending on load and fuel sharing.   Project cost: Rs.33 Lacs per DG    

Details regarding technology absorption

TECHNOLOGY ABSORPTION   In its continuous endeavour to serve the patients better and to bring healthcare of international standards within the reach of every individual, your company has introduced the latest technologies in its hospitals.   Endoscopy Cart for GI Surgery ICG (Indocyanine Green) – Enhanced Fluorescence Guided Laparoscopic Surgery Initially, Indocyanine green (ICG) was used in clinical applications to measure cardiac output, to study the anatomy of retinal vessels and to determine liver functional reserve before hepatic resection in cirrhotic livers. ICG dye can be injected into the human blood stream with practically no adverse effects. ICG becomes fluorescence once excited with light of a specific wavelength in the NIR spectrum delivered by a Xenon Light source or NIR Laser device. Fluorescence can be detected using specific scopes & cameras, then transmitted to a video screen, thus enabling the observer to visualize the areas of anatomical interest where the dye has accumulated (eg: Biliary ducts, vessels, lymph nodes.) In the recent years, ICG-enhanced fluorescence has been introduced in laparoscopic surgery to improve visualization and provide detailed anatomical information during the surgery. ICG- enhanced fluorescence imaging provides for improved visualization of the biliary duct system and tracing the flow of bile, intraoperative evaluation of lymphatic drainage, sentinel lymph node mapping, identification of vascular anatomy, and for perfusion control of solid organs, colon and rectum. The video camera is connected to an ICG Laparoscope (Manufactured By KARL STORZ) equipped with a special filter for optimal reproduction during ICG- enhanced florescence and standard white light imaging.  Switching from standard white light mode to near-infrared mode is simply done via foot-pedal control. Cost involved there in for endoscopy system is approx. Rs 25 lacs. Anesthesia Machine for OT Area The 9100c NXT is the new upgraded platform of Wipro GE’s gold standard product 9100c. This is ideal solution for clinicians seeking a precise, versatile and dependable anesthesia system and has neonatal capabilities and ventilation modes that make it a versatile choice for all types of day care, low-medium acuity and multi-specialty hospitals. It is based on GE/DatexOhmeda's legacy of 100+ years of innovation and trust. This product is scalable across a wide range of patient groups and surgical procedures. The cost involved therein is approx. Rs 20 Lacs. EECP Therapy System for Cardiology EECP© is a Non-Invasive treatment for patients with refractory angina and heart failure. Enhanced External Counter Pulsation (EECP) is performed as a non-invasive treatment to lower the number and intensity of angina episodes. Treatment is administered through three pairs of external inflatable cuffs that are applied around the lower legs, upper legs and buttocks. These cuffs continuously inflate and deflate between the resting period of the heartbeat and increase blood returned to the heart.   The basic principle of EECP treatment involves increasing the amount of blood returning to the heart, which helps supply more oxygen to its starved areas. With more oxygen available, the heart can function much more efficiently and therefore reduce chest pain.  Cost involved there in for EECP Therapy System is approx. Rs 50 lacs. C-Arm Cios fit for Ortho Surgery This is a smart dose management system specially designed for the Cios C-arm family. It continuously analyses each and every one of the image sensor pixels and constantly optimizes their dose efficiency. The result is an always optimized balance of image quality and dose as well as automatic contrast and brightness regulation. Automatic metal exclusion and optimized balance of image quality and dose. Integrated dose measuring chamber with automatic transfer of the accumulated dose into a radiation report. Cost involved there in for C-arm System is approx. Rs 21 lacs.   Vitek MS for microbiology VITEK® MS is an automated mass spectrometry microbial identification system that uses Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology.  NEW!  After recent additions of my cobacteria, Nocardia and moulds, the VITEK ® MS comprehensive CE - marked database now also includes Brucella, Candida auris and Elizabeth kingiaanophelis. In just minutes, VITEK® MS can provide single-choice identifications at the species, genus, or group level. With both VITEK® MS and the VITEK® 2, clinicians receive quick information to adjust therapy for better overall patient care and outcomes. bioMérieux’s proprietary Advanced Spectra Classifier offers robust and accurate results needed for optimal patient-care decisions. The VITEK® MS system reads each spectrum as a series of peaks that are detected and sorted by mass and intensity. With the use of the Advanced Spectra Classifier, better discrimination is provided as every peak is considered in the calculation of the identification result. . Cost involved there in for Vitek MS System is approx. Rs 1.4 Cr. Real Time PCR System for hematology Thermo Fisher Scientific has developed high performance, superior, real-time PCR (qPCR) instruments for laboratories all over the world. During this time, they have also committed to developing systems to meet the specific needs of clinical, diagnostic, and assay developers—with the increased security and compliance of an IVD medical device. The Applied Bio systems Quant Studio 5 DX Real-Time PCR system is the latest additional to our CE-IVD marked quantitative PCR system portfolio. It delivers proven performance and support to help meet the needs of clinical/hospital laboratories and test developers, in a compact footprint and cost-effective package. The Quant Studio 5 Dx Real-Time PCR instrument features: ·         An enhanced user experience with the intuitive software that you have come to expect from smart devices ·         Intelligent, multi-modal software that allows you to move between IVD and development modes in a single instrument ·         A simplified interface that allows you to set up a run, lay out assays, control the instrument, and conduct plate analysis within a single, easy-to-use software ·         Affordability and accessibility with low cost of ownership ·         Enhanced security, including auditing and e-signature functionalities ·         A protected IVD test menu that allows only authorized IVD tests to be run through IVD mode, helping to reduce the risk of unauthorized, accidental or intentional misuse Cost involved there in for Quant Studio 5 Dx Real-Time PCR instrument is approx. Rs 23 lacs.   InterX unit for neuroreheb E-LINK is a computerized modular system bringing both evaluation and exercise together in an exciting format with an extensive scope of clinical applications for the upper and lower extremities: Precise objective measurements can be undertaken very early in hand therapy and continue throughout the full rehabilitation process, with E-LINK providing comprehensive progress reports including impairment calculations. E-LINK sensors, using EMG, enable innovative exercise to begin from a small flicker of muscular activity, even with no visible joint movement - ideal for stroke and neuro rehabilitation. E-LINK ForcePlates assist desensitization exercise from the touch of one finger through to full weight-bearing evaluation and exercise for standing balance. Cost involved there in for Vitek MS System is approx. Rs 20 Lacs.    

Details regarding foreign exchange earnings and outgo

FOREIGN EXCHANGE EARNINGS AND OUTGO:   Particulars Rs. in Crore Current year Previous year Foreign  Exchange Earnings 118.49 144.70 Foreign Exchange outgo ( remittance) 9.03 38.01    

Disclosures in director’s responsibility statement

Pursuant to the requirement of the Companies Act, 2013, the Board of Directors confirms that:   (a)   In the preparation of the annual accounts for the year ended 31st March,2020, the applicable accounting standards had been followed along with proper explanation relating to material departures;   (b)   the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year 2020 and of the profit of the company for that period;   (c)    the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for  safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;   (d)   the directors had prepared the annual accounts on a going concern basis; and   (e)    the directors, had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.   the directors had devised proper systems to ensure compliance with the provision of all applicable laws and that such systems were adequate and operating effectively.   

Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.